Search


	Podcast:		The Bio Report
	Episode:		Should Investors Temper Their Enthusiasm for CAR-T Therapies
	Category:		Business
	Duration:		00:24:23
	Publish Date:		2015-02-05 10:21:34
	Description:		CAR-T cell immunotherapies seek to harness the body’s immune system to fight tumor cells. The promise of this new class of therapies has ignited investor’s imaginations, but a new report from EP Vantage argues that the enthusiasm that has driven valuations of CAR-T companies should be tempered by an eye towards the risks. We spoke to Jacob Plieth, report author and senior reporter for EP Vantage, about the promise of these therapies, what we know about their safety and efficacy, and why the muddy intellectual property landscape is a concern.
	Total Play:		0

Some more Podcasts by Levine Media Group

600+ Episodes

The Bio Repo ..